1037754-65-6 Usage
General Description
(E)-3-(1-(tert-butoxycarbonyl)piperidin-4-yl)but-2-enoic acid is a chemical compound with the molecular formula C15H25NO4. It is a derivative of piperidine, a heterocyclic amine commonly found in pharmaceutical drugs and organic compounds. The compound contains a tert-butoxycarbonyl (Boc) protecting group on the piperidine nitrogen and an (E)-but-2-enoic acid functional group. The Boc protecting group is commonly used in organic synthesis to protect reactive functional groups from undesired reactions. (E)-3-(1-(tert-butoxycarbonyl)piperidin-4-yl)but-2-enoic acid may have applications in medicinal chemistry, organic synthesis, and as a building block for more complex organic molecules. Its specific properties and potential uses would need to be further investigated through experimentation and analysis.
Check Digit Verification of cas no
The CAS Registry Mumber 1037754-65-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,7,7,5 and 4 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1037754-65:
(9*1)+(8*0)+(7*3)+(6*7)+(5*7)+(4*5)+(3*4)+(2*6)+(1*5)=156
156 % 10 = 6
So 1037754-65-6 is a valid CAS Registry Number.
1037754-65-6Relevant articles and documents
PIPERIDINYL GPCR AGONISTS
-
Page/Page column 15, (2010/04/03)
Compounds of formula (I):or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of diabetes and obesity.
HETEROCYCLIC GPCR AGONISTS
-
Page/Page column 22, (2010/04/03)
Compounds of formula (I) or pharmaceutically acceptable salts thereof, are GPCR (GPR119) agonists and are useful as for the treatment of diabetes and obesity.
COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
-
Page/Page column 19, (2009/04/25)
The present invention is directed to therapeutic compounds which have dual activity as agonists of GPR119 and inhibitors of DPP-IV and are useful for the treatment of metabolic disorders including type II diabetes.
